GCP
SRPT icon

Garda Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Garda Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,470
Closed -$447K – 671
2025
Q1 		$668K Buy
+10,470
New +$1.1M 0.02% 489

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Garda Capital Partners's SRPT Position: Q2 2025 in Review

Garda Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 10,470 shares — an estimated $447K sold.

Garda Capital Partners first reported a position in SRPT in Q1 2025 and held it in 1 quarter. The position peaked at $668K in Q1 2025. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Garda Capital Partners reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Garda Capital Partners sold 10,470 Sarepta Therapeutics shares in Q2 2025, an estimated $447K.
  • Garda Capital Partners first reported a position in Sarepta Therapeutics in Q1 2025 and held it in 1 quarter.
  • Garda Capital Partners's Sarepta Therapeutics position peaked at $668K in Q1 2025.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Garda Capital Partners's 13F filing for Q2 2025, filed 7 Aug 2025.